Syngene International has announced new investment in peptide laboratory and advanced automation to accelerate drug discovery and development in India. The investments include a dedicated peptide laboratory in Bengaluru and the integration of automation across Drug Metabolism and Pharmacokinetics (DMPK) and Direct-to-Biology (D2B) workflows in Hyderabad. The company hopes the site upgrades will boost scalability, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!